For most of the history of Alzheimer’s disease, there was no way to know whether the pathological changes associated with it were occurring in a living person’s brain until symptoms had already appeared — and often not even then with certainty. Confirming Alzheimer’s pathology in a living person required either an amyloid PET scan costing several thousand dollars, or a lumbar puncture to analyze cerebrospinal fluid. Neither was practical for routine preventive assessment.

That is now changing, and the pace of change has been remarkable. Over the past several years, a new class of blood-based biomarkers has emerged that can detect Alzheimer’s-related brain changes with a level of accuracy that would have seemed improbable a decade ago. Four blood tests have now been cleared by the FDA to help evaluate people who already have memory or thinking symptoms.

This matters enormously for prevention. If the goal is to intervene before symptoms appear — during the long pre-symptomatic window when addressing modifiable risk factors is most likely to help — then we need tools that can detect what is happening in the brain years before a person notices anything is wrong. Blood biomarkers are becoming that tool.

Why Biomarkers Change the Prevention Equation

Alzheimer’s disease is not a condition that begins when symptoms begin. Amyloid-beta plaques can begin to build up in the brain 15 to 20 years or more before memory symptoms appear (Bateman, NEJM 2012; Jansen, JAMA 2015), and tau tangles follow in the years after.3411 By the time most people receive a clinical diagnosis, significant and largely irreversible neuronal loss has already occurred.

This is the fundamental problem with waiting for symptoms. It is analogous to discovering atherosclerotic heart disease only after a heart attack — technically correct as a diagnosis, but far too late to have prevented the event.

Blood biomarkers give us a way to look inside the brain during that silent interval. A person who is cognitively normal today but shows elevated amyloid-related markers in their blood is not a person to reassure and send home. They are a person to engage in intensive, evidence-based preventive intervention — sleep optimization, metabolic health management, exercise, targeted pharmacological strategies where appropriate — during the window when those interventions are most likely to matter.

The Key Biomarkers: What Each One Measures

Phosphorylated Tau 217 (p-tau 217)

Of the currently available blood biomarkers, p-tau 217 has emerged as the strongest performer for Alzheimer’s-specific pathology. Tau is a protein that stabilizes the internal structure of neurons. In Alzheimer’s disease, tau becomes abnormally phosphorylated at specific sites and aggregates into neurofibrillary tangles — one of the two defining pathological features of the disease.

P-tau 217 in particular appears to rise early in the Alzheimer’s disease continuum, correlating well with amyloid burden as measured by PET imaging. Multiple large studies, including work published in JAMA (Palmqvist, 2020) and Nature Medicine (Barthélemy, 2024), have demonstrated that p-tau 217 can distinguish Alzheimer’s pathology from other causes of cognitive change with an accuracy matching that of FDA-approved cerebrospinal fluid tests, about 90 percent in people with cognitive impairment — a meaningful threshold.12 Performance varies by laboratory and assay, and not every commercial test reaches this level.

Clinically, elevated p-tau 217 in a cognitively normal person does not mean they will inevitably develop Alzheimer’s dementia. It means the underlying pathological process is underway, which changes the risk calculation and the urgency of preventive intervention.

Amyloid 42/40 Ratio

Amyloid-beta is the other defining pathological feature of Alzheimer’s disease. In a healthy brain, amyloid is produced and cleared continuously. In Alzheimer’s disease, a specific form — amyloid-beta 42 — begins to misfold and aggregate into plaques. As this happens, the concentration of amyloid-beta 42 in the blood falls, while amyloid-beta 40 (a shorter, more soluble form) remains relatively stable.

The ratio of amyloid-beta 42 to amyloid-beta 40 is therefore a more reliable signal than either measurement alone. A low 42/40 ratio suggests that amyloid-beta 42 is being sequestered in the brain rather than circulating in the blood — an early indicator of amyloid pathology.

This biomarker is most useful as a screening signal. It is less accurate than p-tau 217, and results vary considerably between laboratories, so a low ratio on its own does not confirm Alzheimer’s pathology (Janelidze, JAMA Neurology 2021)8, but it raises the signal to pursue more specific evaluation.

Glial Fibrillary Acidic Protein (GFAP)

GFAP is a structural protein released by astrocytes — the support cells of the brain — when they are injured or activated in response to neurodegeneration. Elevated blood GFAP levels reflect ongoing neuroinflammatory processes and astrocyte reactivity, which are present in Alzheimer’s disease but also in other forms of neurodegeneration and brain injury.

GFAP is not Alzheimer’s-specific, but it adds useful information in combination with other markers. Elevated GFAP in the context of abnormal p-tau 217 and amyloid ratio strengthens the signal considerably. Whether GFAP can track the effect of lifestyle changes over time is still a research question.

Neurofilament Light Chain (NfL)

NfL is a structural protein released into the blood when axons — the long projections of neurons that carry signals — are damaged. It is a marker of neurodegeneration broadly, not specific to Alzheimer’s disease. Elevated NfL is seen in Alzheimer’s, frontotemporal dementia, ALS, multiple sclerosis, and traumatic brain injury, among others.

Its value in the context of Alzheimer’s risk assessment is as a measure of the rate and extent of neuronal injury. A person with normal amyloid and tau markers but elevated NfL may have another process causing neurodegeneration that warrants investigation. A person with Alzheimer’s-specific markers and elevated NfL has evidence of both the disease process and active neuronal damage — a more urgent picture.

NfL also has a role in monitoring. In patients who have been identified as high risk and are pursuing aggressive preventive strategies, a declining NfL trend over time can serve as one indicator that the intervention is reducing ongoing neurodegeneration, though this application is still being validated in research settings.

What an Abnormal Result Means — and Does Not Mean

This is where clinical judgment is essential, and where the direct-to-consumer blood biomarker market creates real risk of harm through misinterpretation.

An elevated p-tau 217 or a low amyloid 42/40 ratio does not mean you have Alzheimer’s disease. It means there is evidence of Alzheimer’s-related pathological processes occurring in your brain. The distinction is not semantic — it has direct implications for how the information should be interpreted and acted upon.

Several important caveats apply to every biomarker result:

No single biomarker is definitive. These tests are interpreted as a panel, in the context of a patient’s age, genetic risk (particularly APOE status), cognitive testing results, family history, and clinical examination. A single elevated marker in isolation changes the probability estimate; it does not make a diagnosis.

False positives and false negatives occur. Accuracy differs between assays, most of all for the amyloid 42/40 ratio, and kidney function and body weight can shift some markers, especially NfL and GFAP (Pichet Binette, Alzheimer’s & Dementia 2023).9 This is another reason biomarker results require clinical interpretation rather than direct-to-consumer reporting.

Risk is not destiny. Even in people with two copies of APOE4, the highest-risk common genotype, Alzheimer’s biology is nearly universal by the mid-60s (Fortea, Nature Medicine 2024),10 but the age and course of symptoms still vary. Lifestyle, metabolic health, sleep, and other modifiable factors influence whether and when pathological processes translate into clinical symptoms. Knowing your biomarker status is most valuable precisely because it creates the opportunity to act on that modifiable risk.

A normal result is not a guarantee. Normal biomarkers at age 48 do not mean the same pathological process will not begin at 55 or 60. For high-risk individuals, repeat testing over time has clinical value.

How Biomarkers Fit Into a Comprehensive Risk Assessment

In my practice, blood biomarkers are one component of a broader picture that includes:

Biomarkers inform this picture; they do not replace it. A patient who is APOE4 positive, has borderline metabolic health, sleeps poorly, and shows elevated p-tau 217 requires a different and more intensive conversation than one who is APOE4 negative with normal biomarkers and excellent metabolic health — even if both are cognitively asymptomatic today.

Who Should Consider Blood Biomarker Testing

Current guidelines (Alzheimer’s Association, 2025) and FDA clearances cover people who already have cognitive symptoms.712 For people without symptoms, testing is an individual decision made with a physician, with the understanding that its role in guiding prevention is still being studied. In my practice, these are the situations where that conversation most often comes up:

Testing is not appropriate as a standalone consumer product without clinical context. It is appropriate as part of a relationship with a physician who can interpret the results, explain what they mean for that specific individual, and — critically — translate the information into a personalized prevention plan.

The Practical Reality

The pace of development in this field is genuinely rapid. Four blood tests are now FDA-cleared, all for adults who already have cognitive symptoms. Other versions are offered through reference laboratories without FDA review. Reimbursement is evolving. The clinical guidelines are catching up to the science.

What is already clear is that the era of waiting for symptoms before thinking seriously about Alzheimer’s is ending. The tools now exist to identify the disease process during the window when intervention is most meaningful. The question is whether patients and clinicians will use them.

In my practice, that answer is yes. For patients who are willing to engage with the full picture of their brain health — genetic risk, biomarkers, cognitive baseline, metabolic health, sleep — we can construct a prevention strategy that is genuinely personalized rather than generic. That is a different kind of medicine than most people have experienced. It is the kind that has a chance of actually changing outcomes.


Dr. Nadir Bilici is a board-certified neurologist (ABPN) and Diplomate of the International Board of Lifestyle Medicine specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients by telehealth in the states where he is licensed, with in-person appointments available on a select basis.

References

  1. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134
  2. Barthélemy NR, Salvadó G, Schindler SE, et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30(4):1085-1095. doi:10.1038/s41591-024-02869-z
  3. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753
  4. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0
  5. Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671
  6. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400. doi:10.1038/s41467-021-23620-z
  7. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535
  8. Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382. doi:10.1001/jamaneurol.2021.3180
  9. Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403-1414. doi:10.1002/alz.12787
  10. Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med. 2024;30(5):1284-1291. doi:10.1038/s41591-024-02931-w
  11. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668
  12. U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer's disease. May 16, 2025. fda.gov
  13. Alzheimer's Association. FDA clearance of Elecsys pTau217 blood test for Alzheimer's. 2026. alz.org

Written and medically reviewed by Nadir Bilici, MD, DipIBLM. Published February 2026 · Medically reviewed on . See our editorial policy.